Changes in the peripheral blood and bone marrow from untreated advanced breast cancer patients that are associated with the establishment of bone metastases

被引:0
作者
Leandro Marcelo Martinez
Valeria Beatriz Fernández Vallone
Vivian Labovsky
Hosoon Choi
Erica Leonor Hofer
Leonardo Feldman
Raúl Horacio Bordenave
Emilio Batagelj
Federico Dimase
Ana Rodriguez Villafañe
Norma Alejandra Chasseing
机构
[1] National Council of Scientific and Technical Research (CONICET),Immunohematology Laboratory, Experimental Biology and Medicine Institute (IBYME)
[2] Institute for Regenerative Medicine at Scott & White,Texas A&M Health Science Center, College of Medicine
[3] Favaloro Fundation,Department of Bone Marrow Transplantation
[4] Iriarte Hospital,Department of Oncology
[5] Central Militar Hospital,Department of Oncology
[6] Central Militar Hospital,Department of Hemotherapy
[7] Central Militar Hospital,Department of Diagnosis and Treatment
来源
Clinical & Experimental Metastasis | 2014年 / 31卷
关键词
Breast cancer; Bone marrow; Pre-metastatic niche; Mesenchymal stem cells; Bone metastasis;
D O I
暂无
中图分类号
学科分类号
摘要
Bone metastasis is an incurable complication of breast cancer affecting 70–80 % of advanced patients. It is a multistep process that includes tumour cell mobilisation, intravasation, survival in the circulation, extravasation, migration and proliferation in the bone marrow/bone. Although novel findings demonstrate the bone marrow microenvironment significance in bone metastatic progression, a majority of studies have focused on end-stage disease and little is known about how the pre-metastatic niche arises in the bone marrow/bone tissues. We demonstrated a significant increase in patients’ peripheral blood plasma ability to induce transendothelial migration of MCF-7 cells compared with healthy volunteers. Moreover, high RANKL, MIF and OPG levels in patients’ peripheral blood could play a role in the intravasation, angiogenesis, survival and epithelial–mesenchymal transition of circulating tumour cells. Also, we observed a significant increase in patients’ bone marrow plasma capacity to induce transendothelial migration of MDA-MB231 and MCF-7 cells compared with healthy volunteers. Furthermore, patients’ bone marrow mesenchymal stem cells could control the recruitment of tumour cells, modifying the MCF-7 and MDA-MB231 cell migration. In addition, we found a significantly higher MDA-MB231 cell proliferation when we used patients’ bone marrow plasma compared with healthy volunteers. Interestingly, PDGF-AB, ICAM-1 and VCAM-1 levels in patients’ bone marrow were significantly higher than the values of healthy volunteers, suggesting that they could be involved in the cancer cell extravasation, bone resorption and cancer cell proliferation. We believe that these results can reveal new information about what alterations happen in the bone marrow of advanced breast cancer patients before bone colonisation, changes that create optimal soil for the metastatic cascade progression.
引用
收藏
页码:213 / 232
页数:19
相关论文
共 50 条
[41]   Detection of occult cancer cells in peripheral blood and bone marrow by quantitative RT-PCR assay for cytokeratin-7 in breast cancer patients [J].
Masuda, TA ;
Kataoka, A ;
Ohno, S ;
Murakami, S ;
Mimori, K ;
Utsunomiya, T ;
Inoue, H ;
Tsutsui, S ;
Kinoshita, J ;
Masuda, N ;
Moriyama, N ;
Mori, M .
INTERNATIONAL JOURNAL OF ONCOLOGY, 2005, 26 (03) :721-730
[42]   Immunohistochemical Predictors of Bone Metastases in Breast Cancer Patients [J].
Winczura, Piotr ;
Sosinska-Mielcarek, Katarzyna ;
Duchnowska, Renata ;
Badzio, Andrzej ;
Lakomy, Joanna ;
Majewska, Hanna ;
Peksa, Rafal ;
Pieczynska, Beata ;
Radecka, Barbara ;
Debska-Szmich, Sylwia ;
Adamowicz, Krzysztof ;
Biernat, Wojciech ;
Jassem, Jacek .
PATHOLOGY & ONCOLOGY RESEARCH, 2015, 21 (04) :1229-1236
[43]   Pharmacotherapy of bone metastases in breast cancer patients - an update [J].
Jacobs, Carmel ;
Simos, Demetrios ;
Addison, Christina ;
Ibrahim, Mohammed ;
Clemons, Mark .
EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (08) :1109-1118
[44]   Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases [J].
Generali, D. ;
Dovio, A. ;
Tampellini, M. ;
Tucci, M. ;
Tedoldi, S. ;
Torta, M. ;
Bonardi, S. ;
Allevi, G. ;
Aguggini, S. ;
Milani, M. ;
Harris, A. L. ;
Bottini, A. ;
Dogliotti, L. ;
Angeli, A. ;
Berruti, A. .
BRITISH JOURNAL OF CANCER, 2008, 98 (11) :1753-1758
[45]   Gamma knife radiosurgery in patients with advanced breast cancer undergoing bone marrow transplant [J].
Levin, KJ ;
Youssef, EF ;
Sloan, AE ;
Patel, R ;
Zabad, RK ;
Zamorano, L .
JOURNAL OF NEUROSURGERY, 2002, 97 :663-665
[46]   Prevention of Bone Metastases in Breast Cancer Patients. Therapeutic Perspectives [J].
Beuzeboc, Philippe ;
Scholl, Suzy .
JOURNAL OF CLINICAL MEDICINE, 2014, 3 (02) :521-536
[47]   Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases [J].
D Generali ;
A Dovio ;
M Tampellini ;
M Tucci ;
S Tedoldi ;
M Torta ;
S Bonardi ;
G Allevi ;
S Aguggini ;
M Milani ;
A L Harris ;
A Bottini ;
L Dogliotti ;
A Angeli ;
A Berruti .
British Journal of Cancer, 2008, 98 :1753-1758
[48]   Appearance of untreated bone metastases from breast cancer on FDG PET/CT: importance of histologic subtype [J].
Dashevsky, Brittany Z. ;
Goldman, Debra A. ;
Parsons, Molly ;
Goenen, Mithat ;
Corben, Adriana D. ;
Jochelson, Maxine S. ;
Hudis, Clifford A. ;
Morrow, Monica ;
Ulaner, Gary A. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 (11) :1666-1673
[49]   Appearance of untreated bone metastases from breast cancer on FDG PET/CT: importance of histologic subtype [J].
Brittany Z. Dashevsky ;
Debra A. Goldman ;
Molly Parsons ;
Mithat Gönen ;
Adriana D. Corben ;
Maxine S. Jochelson ;
Clifford A. Hudis ;
Monica Morrow ;
Gary A. Ulaner .
European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42 :1666-1673
[50]   Effect of prior therapy and bone marrow metastases on progenitor cell content of blood stem cell harvests in breast cancer patients [J].
Demirkazik, A ;
Kessinger, A ;
Lynch, J ;
Reed, E ;
Tarantolo, S ;
Sharp, JG .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2002, 8 (05) :268-272